Mallia Therapeutics is pioneering the development of soluble CD83 (sCD83) as a novel therapeutic approach for hair loss, particularly targeting conditions such as androgenetic alopecia and alopecia areata. The company’s research, grounded in two decades of expertise, highlights sCD83's dual mode of action: it not only stimulates the formation of new hair follicles but also creates an anti-inflammatory environment that promotes hair regrowth. This human glycoprotein is designed for topical application, ensuring that it does not penetrate the skin and thus minimizes systemic toxicity, making it a safer alternative to existing hair loss treatments.

The efficacy of sCD83 has been demonstrated through various preclinical models, where it has shown significant potential in enhancing hair growth by directly interacting with follicular stem cells. Studies indicate that sCD83 prolongs the anagen (growth) phase of hair follicles and increases the number of new hair follicles. Additionally, it has been observed to induce regulatory T cells, which play a crucial role in hair regeneration. These findings suggest that sCD83 could revolutionize hair loss treatment by addressing both the inflammatory and regenerative aspects of hair follicle biology, offering a promising solution for individuals affected by hair loss.

Germany

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

Mallia Therapeutics

Company Details